189 related articles for article (PubMed ID: 30127950)
1. Expression of V-domain immunoglobulin suppressor of T cell activation is associated with the advanced stage and presence of lymph node metastasis in ovarian cancer.
Liao H; Zhu H; Liu S; Wang H
Oncol Lett; 2018 Sep; 16(3):3465-3472. PubMed ID: 30127950
[TBL] [Abstract][Full Text] [Related]
2. Potential value of V-domain Ig suppressor of T-cell activation for assessing progn osis in cervical cancer and as a target for therapy.
Kuang L; He Y
Int J Clin Exp Pathol; 2020; 13(1):26-37. PubMed ID: 32055269
[TBL] [Abstract][Full Text] [Related]
3. The Expression Pattern and Clinical Significance of the Immune Checkpoint Regulator VISTA in Human Breast Cancer.
Xie X; Zhang J; Shi Z; Liu W; Hu X; Qie C; Chen W; Wang Y; Wang L; Jiang J; Liu J
Front Immunol; 2020; 11():563044. PubMed ID: 33250890
[TBL] [Abstract][Full Text] [Related]
4. VISTA Expression on Immune Cells Correlates With Favorable Prognosis in Patients With Triple-Negative Breast Cancer.
Cao X; Ren X; Zhou Y; Mao F; Lin Y; Wu H; Sun Q
Front Oncol; 2020; 10():583966. PubMed ID: 33505908
[TBL] [Abstract][Full Text] [Related]
5. Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.
Li W; Liu Z; Jin K; Shao F; Zeng H; Wang Y; Zhu Y; Xu L; Wang Z; Chang Y; Zhang W
BMC Cancer; 2023 Jul; 23(1):661. PubMed ID: 37452272
[TBL] [Abstract][Full Text] [Related]
6. High VISTA Expression Correlates With a Favorable Prognosis in Patients With Colorectal Cancer.
Zong L; Yu S; Mo S; Zhou Y; Xiang Y; Lu Z; Chen J
J Immunother; 2021 Jan; 44(1):22-28. PubMed ID: 33086339
[TBL] [Abstract][Full Text] [Related]
7. VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma.
Zhang M; Pang HJ; Zhao W; Li YF; Yan LX; Dong ZY; He XF
BMC Cancer; 2018 May; 18(1):511. PubMed ID: 29720116
[TBL] [Abstract][Full Text] [Related]
8. VISTA expressed in tumour cells regulates T cell function.
Mulati K; Hamanishi J; Matsumura N; Chamoto K; Mise N; Abiko K; Baba T; Yamaguchi K; Horikawa N; Murakami R; Taki M; Budiman K; Zeng X; Hosoe Y; Azuma M; Konishi I; Mandai M
Br J Cancer; 2019 Jan; 120(1):115-127. PubMed ID: 30382166
[TBL] [Abstract][Full Text] [Related]
9. The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy?
Böger C; Behrens HM; Krüger S; Röcken C
Oncoimmunology; 2017; 6(4):e1293215. PubMed ID: 28507801
[TBL] [Abstract][Full Text] [Related]
10. The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead.
Hosseinkhani N; Derakhshani A; Shadbad MA; Argentiero A; Racanelli V; Kazemi T; Mokhtarzadeh A; Brunetti O; Silvestris N; Baradaran B
Front Immunol; 2021; 12():676181. PubMed ID: 34093577
[TBL] [Abstract][Full Text] [Related]
11. Therapy Resistance in Neoadjuvantly Treated Gastric Cancer and Cancer of the Gastroesophageal Junction is Associated with an Increased Expression of Immune Checkpoint Inhibitors-Comparison Against a Therapy Naïve Cohort.
Schoop H; Bregenzer A; Halske C; Behrens HM; Krüger S; Egberts JH; Röcken C
Transl Oncol; 2020 Feb; 13(2):165-176. PubMed ID: 31865179
[TBL] [Abstract][Full Text] [Related]
12. VISTA as a prospective immune checkpoint in gynecological malignant tumors: A review of the literature.
Ren R; Chang X; Chen C; Yu H; Han L
Open Med (Wars); 2023; 18(1):20230866. PubMed ID: 38152334
[TBL] [Abstract][Full Text] [Related]
13. VISTA inhibitors in cancer immunotherapy: a short perspective on recent progresses.
Wu C; Cao X; Zhang X
RSC Med Chem; 2021 Oct; 12(10):1672-1679. PubMed ID: 34778768
[TBL] [Abstract][Full Text] [Related]
14. High VISTA expression is linked to a potent epithelial-mesenchymal transition and is positively correlated with PD1 in breast cancer.
Rezouki I; Zohair B; Ssi SA; Karkouri M; Razzouki I; Elkarroumi M; Badou A
Front Oncol; 2023; 13():1154631. PubMed ID: 37152039
[TBL] [Abstract][Full Text] [Related]
15. VISTA Ligation Reduces Antitumor T-Cell Activity in Pancreatic Cancer.
Digomann D; Strack J; Heiduk M; Plesca I; Rupp L; Reiche C; Nicolaus S; Beer C; Sommer U; Schmitz M; Distler M; Weitz J; Seifert AM; Seifert L
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190254
[TBL] [Abstract][Full Text] [Related]
16. Structure and Functional Binding Epitope of V-domain Ig Suppressor of T Cell Activation.
Mehta N; Maddineni S; Mathews II; Andres Parra Sperberg R; Huang PS; Cochran JR
Cell Rep; 2019 Sep; 28(10):2509-2516.e5. PubMed ID: 31484064
[TBL] [Abstract][Full Text] [Related]
17. VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy.
Yuan L; Tatineni J; Mahoney KM; Freeman GJ
Trends Immunol; 2021 Mar; 42(3):209-227. PubMed ID: 33495077
[TBL] [Abstract][Full Text] [Related]
18. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma.
Kondo Y; Ohno T; Nishii N; Harada K; Yagita H; Azuma M
Oral Oncol; 2016 Jun; 57():54-60. PubMed ID: 27208845
[TBL] [Abstract][Full Text] [Related]
19. VISTA: a novel immunotherapy target for normalizing innate and adaptive immunity.
ElTanbouly MA; Croteau W; Noelle RJ; Lines JL
Semin Immunol; 2019 Apr; 42():101308. PubMed ID: 31604531
[TBL] [Abstract][Full Text] [Related]
20. Targeting the V-Type Immunoglobulin Domain-Containing Suppressor to T Cell Activation (VISTA) with Agonist Monoclonal Antibodies in Autoimmunity.
Jung M; Bonavida B
Crit Rev Immunol; 2022; 42(4):37-49. PubMed ID: 37022358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
